Nuvalent

Nuvalent is creating precision-targeted therapies for cancer patients, aiming to overcome the limitations of existing therapies on clinically proven kinase targets. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with refined targeting selectivity to overcome resistance, minimize adverse effects, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, as well as multiple discovery-stage research programs.